PreveCeutical Medical (TSE:PREV) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board, bringing his expertise in venture capital and corporate development. Gallagher’s extensive experience in biotech investments and successful leadership in high-profile exits, like the acquisition of Translate Bio by Sanofi, is expected to drive BioGene’s growth in innovative therapies.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.